Redhill Biopharma - ADR

+0.18 (+2.15%)

RedHill Announces Unanimous Dsmb Recommendation To Continue Phase 2/3 COVID-19 Study With Opaganib

Published: 11/19/2020 12:44 GMT
Redhill Biopharma Ltd (RDHL) - Redhill Announces Unanimous Dsmb Recommendation to Continue Phase 2/3 Covid-19 Study With Opaganib.
Redhill Biopharma Ltd - Enrollment in 270-patient Global Phase 2/3 Covid-19 Study With Opaganib is More Than 50% Complete.
Redhill Biopharma - Enrollment Completed in Parallel U.S. Phase 2 Study.
Redhill Biopharma Ltd - Data From Parallel U.S. Phase 2 Study Expected in Coming Weeks.
Redhill Biopharma Ltd - Global Phase 2/3 Study With Opaganib is on Track to Deliver Top Line Data in Q1 of 2021.
Redhill Biopharma Ltd - Prescheduled, Unblinded Futility Interim Analysis for Global Phase 2/3 Study Will Be Conducted by Dsmb in Coming Weeks.
Redhill Biopharma Ltd - Emergency Use Authorization Applications Planned As Early As Q1/2021.